Eli Lilly Partners with Veeva Systems to Implement Vault CRM Globally

Eli Lilly and Veeva Systems Join Forces for Global CRM Implementation

In a significant move to enhance its commercial capabilities, Eli Lilly and Company has officially chosen Veeva Vault CRM for global deployment. This decision is part of a broader strategy to leverage advanced technologies in the commercial model of healthcare, ensuring that innovative medicines reach more patients effectively.

A New Era in Healthcare Technology

Veeva Vault CRM is a comprehensive application suite designed to facilitate a modern approach to customer relationship management, aimed at the life sciences sector. With the integration of artificial intelligence into its framework, Vault CRM represents a shift towards more personalized and efficient outreach strategies. This technology is set to transform how Eli Lilly connects with healthcare professionals (HCPs) and stakeholders in the healthcare ecosystem.

Giuseppe Firenze, senior vice president at Eli Lilly, expressed enthusiasm about this partnership, stating, "We are excited to expand our strategic work with Veeva by moving to Vault CRM. This platform will empower Lilly to deliver its breakthrough medicines to even more patients globally." This statement emphasizes the direct impact that Veeva's technology could have on patient access and healthcare engagement.

Empowering Patients through Innovation

Eli Lilly has a long-standing commitment to developing therapies that improve lives. With the addition of Veeva Vault CRM, the company aims to streamline its operations and enhance its effectiveness in creating tailored solutions for patients. Veeva's CEO, Peter Gassner, noted, "We are proud to expand our strategic work with Lilly as they roll out Vault CRM on a global scale." This not only showcases Veeva's confidence in their product but also acknowledges the potential for significant improvements in patient care through informed pharmacological practices.

Looking Ahead: AI in Healthcare

The adoption of AI within the Vault CRM system symbolizes a critical step towards a future where technology and medicine are more interlinked than ever. Eli Lilly's initiative aligns with broader trends in the pharmaceutical industry, where digitization and smart data utilization are becoming prerequisites for success. By harnessing AI, Eli Lilly can analyze complex data sets more effectively, allowing for timely and accurate decisions in commercial practices.

This integration promises better identification of patient needs, improved response times to market changes, and ultimately, a stronger relationship between the healthcare provider and the patient.

Commitment to Stakeholder Balance

Veeva Systems operates as a Public Benefit Corporation, emphasizing the importance of maintaining a balance between the interests of various stakeholders—customers, employees, shareholders, and partners in healthcare. This approach resonates well with Eli Lilly's mission of prioritizing patient welfare above all.

As both companies move forward with the implementation of Veeva Vault CRM, the healthcare industry will be watching closely. The anticipated results could set new standards in patient care, redefining how pharmaceutical companies approach their marketing and outreach strategies to ensure that life-changing medicines become accessible to those who need them the most.

For more information about Veeva Vault CRM and its innovative offerings like the Agentic Call Report, visit veeva.com/crm.